US4686284A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Production of monomeric human γ-interferon
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1984-09-26
•
Granted: 1987-08-11
•
Expires: 2004-09-26
Abstract
Abstract Monomeric human γ-interferon is efficiently produced by subjecting crude human γ-interferon to gel filtration in the presence of a reducing sulfur compound and a protein-denaturing agent.
Inventors
- 👤 Kiyoshi Nara
- 👤 Susumu Honda
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:55
CPC Classifications
C; C12; C12N; C12N15/00; C07; C07K; C07K1/00; C07K1/107; C07K1/113; C07K1/1133; A; A61; A61P; A61P43/00; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; C12N15/09; C12N15/63; C12N15/70; C12N15/71; Y; Y10; Y10S; Y10S435/00; Y10S435/811; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
28 words
A method for producing monomeric human γ-interferon, which comprises subjecting crude human γ-interferon to gel filtration in the presence of a reducing sulfur compound and a protein-denaturing agent.
Claim 2
Independent Claim
28 words
A method for producing monomeric human γ-interferon, which comprises subjecting crude human γ-interferon to gel filtration in the presence of a reducing sulfur compound and a protein-denaturing agent.
Claim 3
Dependent Claim
16 words
A method according to claim 1, wherein the reducing sulfur compound is an organic sulfur compound.
Claim 4
Dependent Claim
39 words
A method according to claim 2, wherein the organic sulfur compound is a member selected from a group consisting of cysteine, N-acetylcysteine, N-acetylhomocysteine, glutathione (reduced form), thioethanolamine, monothioglycerol, dithiothreitol, thioalkane having 1-7 carbon atoms and formaldehyde sodium sulfoxilate dihydrate.
Claim 5
Dependent Claim
15 words
A method according to claim 3, wherein the organic sulfur compound is glutathione (reduced form).
Claim 6
Dependent Claim
24 words
A method according to claim 1, wherein the protein-denaturing agent is a member selected from a group consisting of guanidine salt, urea and thiocyanate.
Claim 7
Dependent Claim
13 words
A method according to claim 5, wherein the protein-denaturing agent is guanidine salt.
Claim 8
Dependent Claim
16 words
A method according to claim 1, wherein the crude human γ-interferon is a recombinant human γ-interferon.
Claim 9
Dependent Claim
25 words
A method according to claim 1, wherein the crude human γ-interferon is an eluate of an antibody column loaded with an extract containing human γ-interferon.
Claim 10
Dependent Claim
22 words
A method according to claim 1, wherein the gel is a member selected from a group consisting of dextran, polyacrylamide and agarose.
Claim 11
Dependent Claim
11 words
A method according to claim 9, wherein the gel is dextran.
Claim 12
Dependent Claim
48 words
A method according to claim 1, wherein the gel filtration is conducted by loading crude human γ-interferon dissolved in a buffer solution containing a reducing sulfur compound and a protein-denaturing agent on a column packed with granular gel and then eluting the γ-interferon with the same buffer solution.
Claim 13
Dependent Claim
35 words
A method according to claim 11, wherein the buffer solution contains the reducing sulfur compound and the protein-denaturing agent in a concentration of about 1 to 100 mM and about 0.1 to 7 M, respectively.
Claim 14
Dependent Claim
17 words
A method according to claim 11, wherein the buffer solution is of about pH 5.0 to 8.0.
Claim 15
Dependent Claim
20 words
A method according to claim 11, wherein the elution is conducted at a space velocity of about 0.1 to 10.
Claim 16
Dependent Claim
35 words
A method according to claim 1, further comprising a gel filtration step using a gel suited for removing low molecular weight compounds to obtain monomeric human γ-interferon free from reducing sulfur compound and protein-denaturing agent.
References Cited (Backward Citations)
US3981991A
Cited
US4100150A
Cited
US4278661A
Cited
EP0077670A2
Cited
EP0080879A2
Cited
EP0089692A2
Cited
US4432895A
Cited
US4476049A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-08-10 | 1991-02-09 | 1991-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-08-10 | 1995-02-09 | 1995-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-08-10 | 1999-02-09 | 1999-08-11 | $7700.00 | Window Closed / Lapsed |